1. Home
  2. News
  3. Recce Pharmaceuticals Ltd.
  4. Safety Committee Approves Expansion of Ph I/II DFI Trial
More Recce Pharmaceuticals Ltd. news
Recce Pharmaceuticals Ltd.ASX: RCE

Safety Committee Approves Expansion of Ph I/II DFI Trial

Feb 25, 2024 at 10:58 PM EST · Issued by Recce Pharmaceuticals Ltd.

Filed with ASX · Feb 25, 2024 at 10:58 PM EST · 3 pages · English

On 6ix: 6ix.com/news/safety-committee-approves-expansion-of-ph-iii-dfi-trial

Recce Pharmaceuticals Ltd. on 6ix

Story so far

  • Committee Approves Fast 15-Min Infusion in Ph I/II UrosepsisOct 24, 2023

Earlier from Recce Pharmaceuticals

  • RCE Establishes Strategic Partnership in South-East AsiaFeb 5, 2024
  • Positive Ph I/II DFI Efficacy Data to Support Site ExpansionJan 17, 2024
  • Murdoch Children's R327 Efficacy UTI in-vivoDec 27, 2023
  • RCE Awarded Further $11.17m Advanced Overseas FindingDec 15, 2023
  • RCE Awarded $43.7m AusIndustry Advanced Overseas FindingDec 14, 2023

Later from Recce Pharmaceuticals

  • Recce Receives AUD $11.17m R&D AdvanceMar 7, 2024
  • Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical TrialMar 12, 2024
  • Patent Granted in Israel for RECCE Anti-InfectivesApr 2, 2024
  • Recce Pharmaceuticals - Business UpdateApr 7, 2024
  • Recce Completes 5,000 R327 Doses Per Week under GMPApr 16, 2024
All Recce Pharmaceuticals news releases↗

Follow Recce Pharmaceuticals into a list and get an email when it puts out news.

Follow Recce Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer